Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia
Mianmian Yin, Timour Baslan, Robert L. Walker, Yuelin J. Zhu, Amy Freeland, Toshihiro Matsukawa, Sriram Sridharan, André Nussenzweig, Steven C. Pruitt, Scott W. Lowe, Paul S. Meltzer, Peter D. Aplan
Mianmian Yin, Timour Baslan, Robert L. Walker, Yuelin J. Zhu, Amy Freeland, Toshihiro Matsukawa, Sriram Sridharan, André Nussenzweig, Steven C. Pruitt, Scott W. Lowe, Paul S. Meltzer, Peter D. Aplan
View: Text | PDF
Research Article Genetics Hematology

A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia

  • Text
  • PDF
Abstract

Mice homozygous for a hypomorphic allele of DNA replication factor minichromosome maintenance protein 2 (designated Mcm2cre/cre) develop precursor T cell lymphoblastic leukemia/lymphoma (pre-T LBL) with 4–32 small interstitial deletions per tumor. Mice that express a NUP98-HOXD13 (NHD13) transgene develop multiple types of leukemia, including myeloid and T and B lymphocyte. All Mcm2cre/cre NHD13+ mice develop pre-T LBL, and 26% develop an unrelated, concurrent B cell precursor acute lymphoblastic leukemia (BCP-ALL). Copy number alteration (CNA) analysis demonstrated that pre-T LBLs were characterized by homozygous deletions of Pten and Tcf3 and partial deletions of Notch1 leading to Notch1 activation. In contrast, BCP-ALLs were characterized by recurrent deletions involving Pax5 and Ptpn1 and copy number gain of Abl1 and Nup214 resulting in a Nup214-Abl1 fusion. We present a model in which Mcm2 deficiency leads to replicative stress, DNA double strand breaks (DSBs), and resultant CNAs due to errors in DNA DSB repair. CNAs that involve critical oncogenic pathways are then selected in vivo as malignant lymphoblasts because of a fitness advantage. Some CNAs, such as those involving Abl1 and Notch1, represent attractive targets for therapy.

Authors

Mianmian Yin, Timour Baslan, Robert L. Walker, Yuelin J. Zhu, Amy Freeland, Toshihiro Matsukawa, Sriram Sridharan, André Nussenzweig, Steven C. Pruitt, Scott W. Lowe, Paul S. Meltzer, Peter D. Aplan

×

Figure 7

Recurrent Nup214-Abl1 fusion gene detected in BCP-ALL.

Options: View larger image (or click on image) Download as PowerPoint
Recurrent Nup214-Abl1 fusion gene detected in BCP-ALL.
(A) CNAs for the ...
(A) CNAs for the Abl1- and Nup214-containing region of chromosome 2. Color code as in Figure 2A. (B) Schematic for putative Nup214-Abl1 fusion gene produced via episome or tandem duplication. (C) RT-PCR detection of Nup214-Abl1 fusion mRNA using Nup214 exon 29 forward primer and Abl1 exon 2 reverse primer. Pre-T LBL samples are from mice with genotype Mcm2cre/cre NHD13+ and Mcm2cre/cre NHD13–, BCP-ALL samples are from mice with genotype Mcm2cre/cre NHD13–, and AML samples are from mice with genotype Mcm2cre/wt NHD13+. B, bone marrow; T, thymus; LN, lymph node; SP, spleen. (D) RT-PCR does not show Nup214-Abl1 fusion mRNA in BCP-ALL from Mcm2cre/wt NHD13+ mice; 2842 is a positive control. (E) Phosphorylation of Crkl in the spleen of mice (WT, 2842, 2703, 2725, 2905, 2811, 2888, and 2799) with Nup214-Abl1 fusion; v-Abl transformed B cell line is a positive control. (F) Imatinib treatment inhibited the growth of 2725 splenocytes that expressed a Nup214-Abl1 fusion. Growth curves of 2725 splenocytes treated with imatinib for 2 days. Cell number was counted by trypan blue exclusion. Error bars represent standard deviation of 3 technical replicates (n = 3).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts